Results 71 to 80 of about 206 (110)

Neutralizing properties of Varespladib toward group I and II myotoxic phospholipases A2

, 2020
A need exists to develop specific and clinically useful inhibitors of toxic enzymes present in snake venoms, responsible for severe tissue damage and life-threatening effects occurring in thousands of people suffering envenomations globally. LY315920 (Varespladib, S-5920, A-001), a low molecular weight drug developed to inhibit several human secreted ...
Bryan Quirós, Wendy, Fernández Ulate, Julián, Gutiérrez, Jose Maria, Lewin, Matthew R., Lomonte, Bruno   +4 more
openaire   +2 more sources

A concise review on copper catalyzed synthesis of α-ketoamides

Applied Catalysis O: Open
The α-ketoamides are essential building blocks for the synthesis of β-lactams and oxazolidinones. As it contains multiple reactive centers, it could be a suitable starting material for following reactions such as Michael addition reaction, Pictet ...
Amit Gautam, Biswa Ranjan Swain, Sonali B. Jethy, V. Ravichandiran, Sharada Prasanna Swain   +4 more
doaj  

22 New Anti-Inflammatory Therapy for Neonatal Acute Lung Injury: Varespladib (A-001) Inhibits Ex-Vivo Secretory Phospholipase [PDF]

, 2010
Danièle De Luca, Virgilio Carnielli, Joaquim Trias, Angelo Minucci, Ettore Capoluongo   +4 more
openalex   +1 more source

Development of a membrane-disruption assay using phospholipid vesicles as a proxy for the detection of cellular membrane degradation

Toxicon: X
Snakebite envenoming is a global health issue that affects millions of people worldwide, and that causes morbidity rates surpassing 450,000 individuals annually.
Mátyás A. Bittenbinder, Eric Wachtel, Daniel Da Costa Pereira, Julien Slagboom, Nicholas R. Casewell, Paul Jennings, Jeroen Kool, Freek J. Vonk   +7 more
doaj  

Feasibility Study: Varespladib protects rodents from lethal doses of whole bee (Apis mellifera) venom.

James Hearth, Kaitlin Linne, Jerry Harrison, Hossein Zolfaghari, Matthew R. Lewin   +4 more
openalex   +1 more source

Dermonecrosis caused by a spitting cobra snakebite results from toxin potentiation and is prevented by the repurposed drug varespladib

Keirah E. Bartlett, Steven R. Hall, Sean A. Rasmussen, Edouard Crittenden, Charlotte A. Dawson, Laura-Oana Albulescu, William Michael Laprade, Robert A. Harrison, Anthony J. Saviola, Cassandra M. Modahl, Timothy P. Jenkins, Mark C. Wilkinson, José Marı́a Gutiérrez, Nicholas R. Casewell   +13 more
openalex   +1 more source

Pharmacological Inhibition of Phosholipase A2: Results from Phase 3 Clinical Trials with Darapladib and Varespladib in Patients with Cardiovascular Disease

, 2015
Nicola Ferri Chiara Ricci
openalex   +1 more source

Corrigendum to “In vitro anticoagulant effects of Bungarus venoms on human plasma which are effectively neutralized by the PLA2-inhibitor varespladib” [Toxicon Volume 252, December 2024, 108178]

Abhinandan Chowdhury, Bryan G. Fry, Stephen P. Samuel, Ashish Bhalla, Sakthivel Vaiyapuri, Parul Bhargava, Rebecca W. Carter, Matthew R. Lewin   +7 more
openalex   +1 more source

In vitro anticoagulant effects of Bungarus venoms on human plasma which are effectively neutralized by the PLA2-inhibitor varespladib

Abhinandan Chowdhury, Bryan G. Fry, Stephen P. Samuel, Ashish Bhalla, Sakthivel Vaiyapuri, Parul Bhargava, Rebecca W. Carter, Matthew R. Lewin   +7 more
openalex   +1 more source

Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome

Cardiovascular Drugs and Therapy, 2011
Secretory phospholipase A(2) group IIA (sPLA(2-)IIA) concentration and activity are associated with increased risk of cardiovascular events in acute coronary syndrome (ACS) patients. This study evaluated baseline differences in sPLA(2)-IIA concentration and other inflammatory markers in ACS patients with and without diabetes, and the inflammatory ...
Robert S Rosenson
exaly   +5 more sources